| Catalog No. | VK665026 |
|---|
| Species reactivity | Human cytomegalovirus (strain AD169) (HHV-5) (Human herpesvirus 5) |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG1, lambda2 |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Envelope glycoprotein B, gB, UL55 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
P06473 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | NPC21, NPC-21, NPC21, 2467411-25-0 |
|---|
| Background | Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV.
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
